פוסרנול 500 מ"ג טבליות לעיסה - Fosrenol 500 mg chewable tablets
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× |
| ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia | ||||||||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||||||||
| צ×רת ××× ×× | ×××××ת ××¢×ס×ת, CHEWABLE TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||||||||
| ×ת×××× | Fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in CRF patients on haemodyalisis or continuous ambulatory peritoneal dialysis (CAPD).Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels. | ||||||||||||||||||||||||
| |||||||||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| פ××¡×¨× ×× 500 ×"× ××××ת ××¢××¡× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | SHIRE PHARMACEUTICAL CONTRACTS LTD, UK |
| ×©× ××¢× ×ר×ש×× | TAKEDA ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 12/2008. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־21 באפריל 2023 ב־05:45